Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEHAW
Aesther Healthcare Acquisition
$0.01
$0.02
$0.06
$0.33
N/AN/A34,287 shs137,835 shs
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
$0.11
$0.10
$0.08
$11.50
N/AN/AN/A867,698 shs
NexImmune, Inc. stock logo
NEXI
NexImmune
$0.00
$0.04
$0.00
$7.05
N/A1.987,297 shs500 shs
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
$7.10
-4.2%
$7.72
$4.11
$25.00
N/AN/A80,669 shs10,787 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEHAW
Aesther Healthcare Acquisition
0.00%+54.36%+55.56%-54.98%-91.24%
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
0.00%0.00%0.00%0.00%0.00%
NexImmune, Inc. stock logo
NEXI
NexImmune
0.00%0.00%0.00%-99.90%-100.00%
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
+2.63%+2.21%+25.38%+740,999,900.00%+740,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
N/AN/AN/AN/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/AN/AN/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEHAW
Aesther Healthcare Acquisition
0.00
N/AN/AN/A
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
0.00
N/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
0.00
N/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/A
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
N/AN/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/A$3.32 per shareN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
$79.99KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEHAW
Aesther Healthcare Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
N/AN/A0.00N/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
-$32.34M-$18.54N/AN/AN/A-534.32%-213.72%5/29/2025 (Estimated)
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/A0.00N/AN/AN/AN/AN/A

Latest MTFB, AEHAW, NTHI, and NEXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/A-$2.10N/A-$2.10N/A$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/A
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
N/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/A
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
N/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/A
0.66
0.66
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AEHAW
Aesther Healthcare Acquisition
N/A
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
N/A
NexImmune, Inc. stock logo
NEXI
NexImmune
9.85%
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AEHAW
Aesther Healthcare Acquisition
2N/AN/ANot Optionable
MOTIF BIO PLC/S stock logo
MTFB
MOTIF BIO PLC/S
7N/AN/ANot Optionable
NexImmune, Inc. stock logo
NEXI
NexImmune
61.40 million1.19 millionNot Optionable
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
8N/AN/AN/A

Recent News About These Companies

NeOnc Technologies announces global patent portfolio totals 176
NeOnc Sees Share Price Fall Since Going Public
NeOnc Technologies appoints Heshmatpour as President
NeOnc Technologies announces NEO212 trial nears full enrollment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.01 0.00 (0.00%)
As of 05/27/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

MOTIF BIO PLC/S stock logo

MOTIF BIO PLC/S NASDAQ:MTFB

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

NexImmune stock logo

NexImmune NASDAQ:NEXI

$0.0001 0.00 (0.00%)
As of 12:09 PM Eastern

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Neonc Technologies stock logo

Neonc Technologies NASDAQ:NTHI

$7.10 -0.31 (-4.18%)
As of 04:00 PM Eastern

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.